eMedicine Specialties > Nephrology > Acid-Base, Fluid, and Electrolyte Disorders

Hyponatremia

Author: Eric E Simon, MD, Associate Professor, Department of Medicine, Tulane University School of Medicine; Co-Director of Nephrology Training, Medical Director, Dialysis Clinic, Inc
Coauthor(s): Seyed Mehrdad Hamrahian, MD, Staff Nephrologist, Ochsner Medical Center
Contributor Information and Disclosures

Updated: May 29, 2009

Introduction

Background

Hyponatremia is an important and common electrolyte abnormality that can be seen in isolation or, as most often is the case, as a complication of other medical illnesses.

Sodium is the dominant extracellular cation and cannot freely cross the cell membrane. Its homeostasis is vital to the normal physiologic function of cells. The normal serum sodium level is 135-145 mEq/L. Hyponatremia is defined as a serum level of less than 135 mEq/L and is considered severe when the serum level is below 125 mEq/L.

This article reviews the epidemiology, pathophysiology, differential diagnosis, evaluation, and treatment of this disorder.

Pathophysiology

Hypoosmolality (serum osmolality <260 mOsm/kg) always indicates excess total body water relative to body solutes or excess water relative to solute in the extracellular fluid (ECF), as water moves freely between the intracellular compartment and the extracellular compartment. This imbalance can be due to solute depletion, solute dilution, or a combination of both.

In the normal condition, renal handling of water is sufficient to excrete as much as 15-20 L of free water per day. Further, in the normal condition, the body's response to a decreased osmolality is decreased thirst. Thus, hyponatremia can occur only when some condition impairs normal free water excretion.1 Generally, hyponatremia is of clinical significance only when it reflects a drop in the serum osmolality (ie, hypotonic hyponatremia), which is measured directly via osmometry or is calculated as 2(Na) mEq/L + serum glucose (mg/dL)/18 + BUN (mg/dL)/2.8.

The recommendations for treatment of hyponatremia rely on the current understanding of CNS adaptation to an alteration in serum osmolality. In the setting of an acute drop in the serum osmolality, neuronal cell swelling occurs due to the water shift from the extracellular space to the intracellular space (ie, Frank Starling forces). Swelling of the brain cells elicits the following 2 osmoregulatory responses:

  • It inhibits both arginine vasopressin secretion from neurons in the hypothalamus and hypothalamic thirst center. This leads to excess water elimination as dilute urine.
  • There is an immediate cellular adaptation with loss of electrolytes, and over the next few days, there is a more gradual loss of organic intracellular osmolytes.2

Therefore, correction of hyponatremia must take into account the chronicity of the condition. Acute hyponatremia (duration <48h) can be safely corrected more quickly than chronic hyponatremia. Correction of serum sodium that is too rapid can precipitate severe neurologic complications. Most individuals who present for diagnosis, versus individuals who develop it while in an inpatient setting, have had hyponatremia for some time, so the condition is chronic, and correction should proceed accordingly.

Frequency

United States

The incidence of hyponatremia depends largely on the patient population and the criteria used to establish the diagnosis. A hospital incidence of 15-20% is common (defined as a serum sodium level of <135 mEq/L), while only 3-5% of patients who are hospitalized have a serum sodium level of less than 130 mEq/L. Hyponatremia's prevalence is lower in the ambulatory setting.

Mortality/Morbidity

Severe hyponatremia (<125 mEq/L) has a high mortality rate; for instance, when the serum sodium level is less than 105 mEq/L, the mortality is over 50%, especially in alcoholics.3 In patients with acute ST-elevation myocardial infarction, the presence of hyponatremia on admission or early development of hyponatremia is an independent predictor of 30-day mortality, and the prognosis worsens with the severity of hyponatremia.4 Similarly, cirrhotic patients with persistent ascites and a low serum sodium level awaiting transplant have a high mortality risk despite low severity (MELD) scores. The independent predictors ascites and hyponatremia are findings indicative of hemodynamic decompensation.5,6

Race

Hyponatremia affects all races.

Sex

No sexual predilection exists for hyponatremia. However, symptoms are more likely to occur in young women than in men.

Age

Hyponatremia is more common in elderly persons, because they have an increased incidence of comorbid conditions (eg, cardiac, hepatic, or renal failure) that can be complicated by it.

Clinical

History

  • Patients may present to medical attention owing to symptoms directly referable to low serum sodium concentrations. However, many patients present due to manifestations of other medical comorbidities, with hyponatremia being recognized only secondarily. For many people, therefore, the recognition is entirely incidental.
    • Patients may develop clinical symptoms due to the cause of hyponatremia or the hyponatremia itself.
    • Many medical illnesses, such as congestive heart failure, liver failure, renal failure, or pneumonia, may be associated with hyponatremia. These patients frequently present because of primary disease symptomatology (eg, dyspnea, jaundice, uremia, cough).
    • Symptoms range from nausea and malaise, with mild reduction in the serum sodium, to lethargy, a decreased level of consciousness, headache, and (if severe) seizures and coma. Neurologic symptoms most often are due to very low serum sodium levels (usually <115 mEq/L), resulting in intracerebral osmotic fluid shifts and brain edema. This neurologic symptom complex can lead to tentorial herniation with subsequent brain stem compression and respiratory arrest, resulting in death in the most severe cases.
  • The severity of neurologic symptoms correlates well with the rapidity and severity of the drop in serum sodium. A gradual drop in serum sodium, even to very low levels, may be tolerated well if it occurs over several days or weeks, because of neuronal adaptation. The presence of an underlying neurologic disease, like a seizure disorder, or nonneurologic metabolic abnormalities, like hypoxia, hypercapnia, or acidosis, also affects the severity of neurologic symptoms.
  • In interviewing the patient, obtaining a detailed medication history, including information on over-the-counter (OTC) drugs the patient has been using, is important, because many medications may precipitate hyponatremia (eg, antipsychotic medications). A dietary history with reference to salt, protein, and water intake is useful as well. For patients who are hospitalized, reviewing the records of parenteral fluids administered is crucial.

Physical

  • Examination should include orthostatic vital signs and an accurate assessment of volume status. This determination (ie, hypervolemic, euvolemic, hypovolemic) often guides treatment decisions.
  • A full assessment for medical comorbidity also is essential, with particular attention paid to cardiopulmonary and neurologic components of the examination.

Causes

Although the differential diagnosis is quite broad, hyponatremia can be divided into the following clinically useful groupings:

  • Hypertonic hyponatremia: Patients with hypertonic hyponatremia have normal total body sodium and a dilutional drop in the measured serum sodium due to the presence of osmotically active molecules in the serum, which cause a water shift from the intracellular compartment to the extracellular compartment.
    • Glucose produces a drop in the serum sodium level of 1.6 mEq/L for each 100 mg/dL of serum glucose greater than 100 mg/dL. This relationship is nonlinear, with greater reduction in plasma sodium concentrations with glucose concentrations over 400 mg/dL, making 2.4 mEq/L for each 100 mg/dL increase in glucose over 100 mg/dL a more accurate correction factor when the glucose is greater than 400 mg/dL.7
    • Other examples of osmotically active molecules include mannitol (often used to treat brain edema) or maltose (used with intravenous immunoglobulin administration).
  • Normotonic hyponatremia: Severe hyperlipidemia and paraproteinemia can lead to low measured serum sodium concentrations with normal serum osmolality. Normally, the plasma water comprises 92-94% of plasma volume. The plasma water fraction falls with an increase in fats and proteins. The measured sodium concentration in the total plasma volume is respectively reduced, although the plasma water sodium concentration and plasma osmolality are unchanged. This artifactually low sodium (so-called pseudohyponatremia) is secondary to measurement by flame photometry. It can be avoided by direct ion-selective electrode measurement.
  • Hyponatremia posttransurethral resection of the prostate (TURP) or hysteroscopy is caused by absorption of irrigants, glycine, sorbitol, or mannitol, contained in nonconductive flushing solutions used. The degree of hyponatremia is related to the quantity and the rate of fluid absorbed. The plasma osmolality is also variable and changes over time.
    • The presence of a relatively large osmolal gap due to the excess organic solute is diagnostic in the appropriate clinical setting. Symptomatic patients are treated depending on plasma osmolality and volume status of patients with either hypertonic saline in hypoosmolar state or loop diuretic in volume-overloaded patients with normal renal function.
    • Hemodialysis, which will correct the hyponatremia and remove glycine and its toxic metabolites, can be used in patients with end-stage renal disease. Use of isotonic saline as an irrigant instead of glycine with the new bipolar resectoscope for TURP in high-risk patients (with large prostates that require lengthy resection) could avoid this complication, making this disorder a diagnosis of the past.8
  • Hypotonic hyponatremia: Hypotonic hyponatremia always reflects the inability of the kidneys to handle the excretion of free water to match oral intake. It can be divided pathophysiologically into the following categories, according to the effective intravascular volume: hypovolemic, hypervolemic, and euvolemic. These clinically relevant groupings aid in determination of likely underlying etiology and guiding treatment.
    • Hypovolemic hypotonic hyponatremia: This usually indicates concomitant solute depletion, with patients presenting with orthostatic symptoms. The pathophysiology underlying hypovolemic hypotonic hyponatremia is complex and involves the interplay of carotid baroreceptors, the sympathetic nervous system, the renin-angiotensin system, antidiuretic hormone (ADH) secretion (vasopressin), and renal tubular function. In the setting of decreased intravascular volume (eg, severe hemorrhage or severe volume depletion secondary to GI or renal loss, or diuretic use) owing to a decreased stretch on the baroreceptors in the great veins, aortic arch, and carotid bodies, an increased sympathetic tone to maintain systemic blood pressure generally occurs.
    • This increased sympathetic tone, along with decreased renal perfusion secondary to intravascular volume depletion, results in increased renin and angiotensin excretion. This, in turn, results in increased sodium absorption in the proximal tubules of the kidney and consequent decreased delivery of solutes to distal diluting segments, causing an impairment of renal free water excretion. There also is a concomitant increase in serum ADH production that further impairs free water excretion. Because angiotensin is also a very potent stimulant of thirst, free water intake is increased, and, at the same time, water excretion is limited. Together, these changes lead to hyponatremia.
    • Cerebral salt wasting (CSW) is seen with intracranial disorders, such as subarachnoid hemorrhage, carcinomatous or infectious meningitis, and metastatic carcinoma, but especially after neurologic procedures. Disruption of sympathetic neural input into the kidney, which normally promotes salt and water reabsorption in the proximal nephron segment through various indirect and direct mechanisms, might cause renal salt wasting, resulting in reduced plasma volume. Plasma renin and aldosterone levels fail to rise appropriately in patients with CSW despite a reduced plasma volume because of disruption of the sympathetic nervous system. In addition, the release of 1 or more natriuretic factors could also play a role in the renal salt wasting seen in CSW. Volume depletion leads to an elevation of plasma vasopressin levels and impaired free water excretion.
    • Distinguishing between CSW and syndrome of inappropriate ADH secretion (SIADH) can be challenging, because there is considerable overlap in the clinical presentation. Vigorous salt replacement is required in patients with CSW, whereas fluid restriction is the treatment of choice in patients with SIADH. Infusion of isotonic saline to correct the volume depletion is usually effective in reversing the hyponatremia in cerebral salt wasting, since euvolemia will suppress the release of ADH. The disorder is usually transient, with resolution occurring within 3-4 weeks of disease onset.9,10
    • Salt-wasting nephropathy causing hypovolemic hyponatremia may rarely develop in a range of renal disorders (eg, interstitial nephropathy, medullary cystic disease, polycystic kidney disease, partial urinary obstruction) with low salt intake.
    • The treatment of choice for hypovolemic hypotonic hyponatremia is saline infusion.
    • Hypervolemic hypotonic hyponatremia: This is characterized by clinically detectable edema or ascites that signifies an increase in total body water and sodium. Paradoxically, however, a decrease in the effective circulating volume, critical for tissue perfusion, stimulates the same pathophysiologic mechanism of impaired water excretion by the kidney that is observed in hypovolemic hypotonic hyponatremia.
    • Commonly encountered examples include liver cirrhosis, congestive heart failure, nephrotic syndrome, and severe hypoproteinemia (albumin level <1.5-2 g/dL).
    • The treatment of these patients is usually limited to free water restriction and diuresis to induce negative water balance.
    • Patients with renal failure and hyponatremia may have normal or high plasma osmolality because of the urea retention. However, as urea is not an effective osmole, the patient should be treated as per hypotonic hyponatremia.
    • Normovolemic (euvolemic) hypotonic hyponatremia: This is a very common cause of hyponatremia in patients who are hospitalized. It is associated with nonosmotic and nonvolume related vasopressin (ADH) secretion (ie, SIADH) secondary to a variety of clinical conditions, including CNS disturbances, major surgery, trauma, pulmonary tumors, infection, stress, and certain medications.
    • Common medications associated with SIADH are as follows: chlorpropamide (potentiating renal action of ADH), carbamazepine (possesses antidiuretic property), cyclophosphamide (marked water retention secondary to SIADH and potentially fatal hyponatremia may ensue in selected cases; use of isotonic saline rather than free water to maintain a high urine output to prevent hemorrhagic cystitis can minimize the risk), vincristine, vinblastine, amitriptyline, haloperidol, selective serotonin reuptake inhibitors (particularly in elderly patients), and monoamine oxidase (MAO) antidepressants. In these circumstances, the ability of the kidney to dilute urine in the setting of serum hypotonicity is reduced.
    • Diuretics may induce hypovolemic hyponatremia. Note that thiazide diuretics, in contrast to loop diuretics, impair the diluting mechanism without limiting the concentrating mechanism, thereby impairing the ability to excrete a free water load. Thus, thiazides are more prone to causing hyponatremia than are loop diuretics.
    • Hyponatremia is a relatively common adverse effect of desmopressin, a vasopressin analogue that acts as a pure V2 agonist. Its common use in the treatment of central diabetes insipidus, von Willebrand disease, and nocturia in adults and of enuresis in children requires regular monitoring of serum sodium levels.
    • The diagnostic criteria for SIADH are as follows:
      • Normal hepatic, renal, and cardiac function - Clinical euvolemia (absence of intravascular volume depletion)
      • Normal thyroid and adrenal function
      • Hypotonic hyponatremia
      • Urine osmolality greater than 100 mOsm/kg, generally greater than 400-500 mOsm/kg with normal renal function
    • Urinary sodium concentrations are also typically greater than 20 mEq/L on a normal salt diet. Serum uric acid levels are generally reduced; this is due to reduced tubular uric acid reabsorption, which parallels the decrease in proximal tubular sodium reabsorption associated with central volume expansion.
    • Reset osmostat is another important cause of normovolemic hypotonic hyponatremia. This may occur in elderly patients and during pregnancy. These patients regulate their serum osmolality around a reduced set point; however, in contrast to patients with SIADH (who also have a downward resetting of the osmotic threshold for thirst),11 they are able to dilute their urine in response to a water load to keep the serum osmolality around the preset low point.
    • Severe hypothyroidism (unknown mechanism, possibly secondary to low cardiac output and glomerular filtration rate) and adrenal insufficiency are also associated with nonosmotic vasopressin release and impaired sodium reabsorption, leading to hypotonic hyponatremia. Hyponatremia associated with cortisol deficiency, such as primary or secondary hypoadrenalism, commonly presents subtly and may go undiagnosed. A random cortisol level check, especially in acute illness, can be misleading if the level is normal (when it should be high). Testing for adrenal insufficiency and hypothyroidism should be part of the hyponatremic workup, as the disorders respond promptly to hormone replacement. Depending on the etiology, mineralocorticoid will also need replacement.
    • Severe malnutrition seen in weight-conscious women (low protein, high water intake diet) is a special condition in which a markedly decreased intake of solutes occurs, which limits the ability of the kidney to handle the free water. Because a mandatory solute loss of 50-100 mOsm/kg of urine exists, free water intake in excess of solute needs can produce hyponatremia.12 Another example is beer drinker's potomania, because a diet consisting primarily of beer is rich in free water but solute poor.
    • Compulsive intake of large amounts of free water exceeding the dilutional capacity of the kidneys (>20 L/d), even with a normal solute intake of 600-900 mOsm/d, may also result in hyponatremia, but in contrast to SIADH, the urine is maximally dilute. In addition to a central defect in thirst regulation, which plays an important role in the pathogenesis of primary polydipsia, different abnormalities in ADH regulation have been identified in psychotic patients, all impairing free water excretion. Transient stimulation of ADH release during acute psychotic episodes, an increase in the net renal response to ADH, downward resetting of the osmostat, and antipsychotic medication may contribute. Limiting water intake will rapidly raise the plasma sodium concentration as the excess water is readily excreted in dilute urine.13
    • Hospitalized patients who are infected with human immunodeficiency virus (HIV) have a high incidence of hyponatremia. In these individuals, hyponatremia is usually due to at least 1 of the following 3 disorders associated with an increased ADH level:
      • Increased release of ADH due to malignancy, to occult or symptomatic infection of the central nervous system, or to pneumonia resulting from infection with Pneumocystis carinii or other organisms.
      • Effective volume depletion secondary to fluid loss from the gastrointestinal tract, due primarily to infectious diarrhea.
      • Adrenal insufficiency often due to an adrenalitis, an abnormality that may be infectious in origin, perhaps being induced by cytomegalovirus, Mycobacterium avium-intracellulare, or HIV itself. Affected patients have a high risk of morbidity and mortality.
    • Treatment generally is that of the underlying cause and free water restriction.
    • The most common precipitant of hyponatremia in patients after surgery14 is the iatrogenic infusion of hypotonic fluids. Inappropriate administration of hypotonic intravenous fluids after surgery increases the risk of developing hyponatremia in these vulnerable patients, who retain water due to nonosmotic release of ADH, which is typically elevated for a few days after most surgical procedures. Hospital-acquired acute hyponatremia is disturbingly common also among hospitalized children and adults.
    • Acute hyponatremia is associated with ultra-endurance athletes and marathon runners. With women making up a higher percentage, the strongest single predictor is weight gain during the race correlating with excessive fluid intake. Longer racing time and body mass index extremes are also associated with hyponatremia, whereas the composition of fluids consumed (plain water rather than sports drinks containing electrolytes) is not. Oxidization of glycogen and triglyceride during a race is associated with the production of "bound" water, which then becomes an endogenous, electrolyte-free water infusion contributing to hyponatremia induced by water ingestion in excess of water losses.
    • Nonsteroidal anti-inflammatory drug (NSAID) use may increase the risk of development of hyponatremia by strenuous exercise by inhibiting prostaglandin formation. Prostaglandins have a natriuretic effect. Prostaglandin depletion increases NaCl reabsorption in the thick ascending limb of Henle (ultimately increasing medullary tonicity) and ADH action in the collecting duct, leading to impaired free water excretion.15
    • Some collapsed runners are normonatremic or even hypernatremic,16 making blanket recommendations difficult. However, fluid intake to the point of weight gain should be avoided.16,17 Athletes should rely on thirst as their guide for fluid replacement and avoid fixed, global recommendations for water intake. Symptomatic hyponatremic patients should receive 100 mL of 3% sodium chloride over 10 minutes in the field before transportation to hospital. This maneuver should raise the plasma sodium concentration an average of 2-3 mEq/L.18
    • Symptomatic and potentially fatal hyponatremia can develop with rapid onset after ingestion of the designer drug ecstasy (methylenedioxymethamphetamine, or MDMA), an amphetamine. A marked increase in water intake via direct thirst stimulation, as well as inappropriate secretion of ADH, contributes to the hyponatremia seen with even small amount of drug intake.
    • Nephrogenic syndrome of inappropriate antidiuresis (or NSIAD) is an SIADH-like clinical and laboratory picture seen in male infants who present with neurologic symptoms secondary to hyponatremia but who have undetectable plasma arginine vasopressin (AVP) levels. This hereditary disorder is secondary to mutations in the V2 vasopressin receptor, resulting in constitutive activation of the receptor with elevated cAMP production in the collecting duct principle cells. Treatment of NSIAD poses a challenge. Water restriction improves serum sodium levels and osmolality in infants, but it limits calorie intake in these formula-fed infants. The use of demeclocycline or lithium is potentially limited because of adverse effects. The current therapy of choice is fluid restriction and the use of urea to induce an osmotic diuresis.19
    • Hyponatremic hypertensive syndrome, a rare condition, consists of severe hypertension associated with renal artery stenosis, hyponatremia, hypokalemia, severe thirst, and renal dysfunction characterized by natriuresis, hypercalciuria, renal glycosuria, and proteinuria. Angiotensin-mediated thirst coupled with nonosmotic release of vasopressin provoked by angiotensin II and/or hypertensive encephalopathy are likely mechanisms for this syndrome. Sodium depletion due to pressure natriuresis and potassium depletion due to hyperaldosteronism with high plasma renin activity are also likely to play a role in the pathogenesis of hyponatremia. The abnormalities resolve with correction of the renal artery stenosis.20
Using a retrospective case note analysis, an Irish study examined the incidence of hyponatremia in a variety of neurologic conditions.21 The investigators found that the occurrence of hyponatremia was greater in persons with subarachnoid hemorrhage (62 out of 316 patients, or 19.6%; p <0.001), intracranial neoplasm (56 out of 355 patients, or 15.8%; p <0.001), traumatic brain injury (44 out of 457 patients, or 9.6%; p <0.001), and pituitary disorders (5 out of 81 patients, or 6.25%; p = 0.004) than it was in patients with spinal disorders (4 out of 489 patients, or 0.81%).

The investigators also determined that the median hospital stay for patients with hyponatremia was 19 days, compared with a median stay of 12 days for the study's other patients.

More on Hyponatremia

Overview: Hyponatremia
Differential Diagnoses & Workup: Hyponatremia
Treatment & Medication: Hyponatremia
Follow-up: Hyponatremia
References
Further Reading

References

  1. Singhi S, Jayashree M. Free water excess is not the main cause for hyponatremia in critically ill children receiving conventional maintenance fluids. Indian Pediatr. Apr 1 2009;[Medline].

  2. Gross P, Reimann D, Henschkowski J, et al. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol. Feb 2001;12 Suppl 17:S10-4. [Medline].

  3. Dubois GD, Arieff AI. Treatment of hyponatremia: the case for rapid correction. In: Narins RG, ed. Controversies in Nephrology and Hypertension. New York: Churchill Livingstone Inc; 1984:393-407.

  4. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am J Med. Aug 15 2004;117(4):242-8. [Medline].

  5. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. Oct 2004;40(4):802-10. [Medline].

  6. Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. May 16 2009;[Medline].

  7. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. Apr 1999;106(4):399-403. [Medline].

  8. Issa MM, Young MR, Bullock AR, Bouet R, Petros JA. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology. Aug 2004;64(2):298-301. [Medline].

  9. Palmer BF. Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant. Feb 2000;15(2):262-8. [Medline].

  10. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab. May-Jun 2003;14(4):182-7. [Medline].

  11. Smith D, Moore K, Tormey W, et al. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab. Nov 2004;287(5):E1019-23. [Medline].

  12. Thaler SM, Teitelbaum I, Berl T. "Beer potomania" in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis. Jun 1998;31(6):1028-31. [Medline].

  13. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med. Feb 18 1988;318(7):397-403. [Medline].

  14. Skippen P, Adderley R, Bennett M, et al. Iatrogenic hyponatremia in hospitalized children: Can it be avoided?. Paediatr Child Health. Jul 2008;13(6):502-6. [Medline].

  15. Baker J, Cotter JD, Gerrard DF, Bell ML, Walker RJ. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc. May 2005;37(5):712-7. [Medline].

  16. Kratz A, Siegel AJ, Verbalis JG, Adner MM, Shirey T, Lee-Lewandrowski E. Sodium status of collapsed marathon runners. Arch Pathol Lab Med. Feb 2005;129(2):227-30. [Medline].

  17. Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA. Hyponatremia among runners in the Boston Marathon. N Engl J Med. Apr 14 2005;352(15):1550-6. [Medline].

  18. Hew-Butler T, Almond C, Ayus JC, et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med. Jul 2005;15(4):208-13. [Medline].

  19. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. May 5 2005;352(18):1884-90. [Medline].

  20. Trivelli A, Ghiggeri GM, Canepa A, Oddone M, Bava G, Perfumo F. Hyponatremic-hypertensive syndrome with extensive and reversible renal defects. Pediatr Nephrol. Jan 2005;20(1):102-4. [Medline].

  21. Sherlock M, O'Sullivan E, Agha A, et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. Apr 2009;85(1002):171-5. [Medline].

  22. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. May 25 2000;342(21):1581-9. [Medline].

  23. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. Jan-Feb 2003;18(1):3-8. [Medline].

  24. Dixon MB, Lien YH. Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag. Dec 2008;4(6):1149-55. [Medline].

  25. Farmakis D, Filippatos G, Kremastinos DT, et al. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. Jun 2008;5(2):91-6. [Medline].

  26. [Best Evidence] Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. Nov 16 2006;355(20):2099-112. [Medline][Full Text].

  27. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. Dec 1 1992;117(11):891-7. [Medline].

  28. Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol. Feb 2004;25(2):210-3. [Medline].

  29. Yu J, Zheng SS, Liang TB, Shen Y, Wang WL, Ke QH. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol. Sep 1 2004;10(17):2540-3. [Medline].

  30. Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("Ecstasy") abuse. Am J Med Sci. Aug 2003;326(2):89-93. [Medline].

  31. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. Sep 1998;28(3):851-64. [Medline].

  32. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. Jan 1 1990;112(1):35-49. [Medline].

  33. Pham PC, Pham PM, Pham PT. Vasopressin excess and hyponatremia. Am J Kidney Dis. May 2006;47(5):727-37. [Medline].

  34. Santos BC, Chevaile A, Hebert MJ, Zagajeski J, Gullans SR. A combination of NaCl and urea enhances survival of IMCD cells to hyperosmolality. Am J Physiol. Jun 1998;274(6 Pt 2):F1167-73. [Medline].

  35. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. Aug 19 1999;341(8):577-85. [Medline].

  36. Silver SM, Kozlowski SA, Baer JE, Rogers SJ, Sterns RH. Glycine-induced hyponatremia in the rat: a model of post-prostatectomy syndrome. Kidney Int. Jan 1995;47(1):262-8. [Medline].

  37. Silver SM, Schroeder BM, Bernstein P, Sterns RH. Brain adaptation to acute hyponatremia in young rats. Am J Physiol. Jun 1999;276(6 Pt 2):R1595-9. [Medline].

  38. Sterns RH. The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Am J Kidney Dis. Jan 1999;33(1):161-3; discussion 163-5. [Medline].

Keywords

hyponatremia, SIADH, electrolyte, electrolytes, electrolyte imbalance, sodium deficiency, furosemide, hypertonic hyponatremia, hyponatraemia, hyponatremia treatment, hyponatremia causes, hyponatremia correction, tolvaptan, conivaptan, cerebral salt wasting, normotonic hyponatremia, hypotonic hyponatremia, normovolemic hypotonic hyponatremia, euvolemic hypotonic hyponatremia, abnormal electrolyte level, abnormal electrolyte distribution, congestive heart failure, liver failure, renal failure, hyperlipidemia, paraproteinemia, pseudohyponatremia, liver cirrhosis, nephrotic syndrome, severe hypoproteinemia, syndrome of inappropriate ADH secretion, severe hypothyroidism, adrenal insufficiency

Contributor Information and Disclosures

Author

Eric E Simon, MD, Associate Professor, Department of Medicine, Tulane University School of Medicine; Co-Director of Nephrology Training, Medical Director, Dialysis Clinic, Inc
Eric E Simon, MD is a member of the following medical societies: American Federation for Medical Research, American Heart Association, American Society for Cell Biology, American Society of Nephrology, Association for Psychological Science, Central Society for Clinical Research, International Society of Nephrology, National Kidney Foundation, Phi Beta Kappa, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

Coauthor(s)

Seyed Mehrdad Hamrahian, MD, Staff Nephrologist, Ochsner Medical Center
Seyed Mehrdad Hamrahian, MD is a member of the following medical societies: American Society of Nephrology and National Kidney Foundation
Disclosure: Nothing to disclose.

Medical Editor

James H Sondheimer, MD, Director of Hemodialysis Unit, Harper Hospital; Associate Professor, Department of Internal Medicine, Division of Nephrology, Wayne State University School of Medicine
James H Sondheimer, MD is a member of the following medical societies: American College of Physicians and American Society of Nephrology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Eleanor Lederer, MD, Consulting Staff, Louisville VA Hospital; Professor of Medicine, Director of Nephrology Training Program, Kidney Disease Program, University of Louisville School of Medicine; Director, Metabolic Stone Clinic
Eleanor Lederer, MD is a member of the following medical societies: American Association for the Advancement of Science, American Federation for Medical Research, American Society for Biochemistry and Molecular Biology, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine
Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association
Disclosure: Abbott Grant/research funds Speaking and teaching; Genzyme Honoraria Consulting; Amgen Honoraria Speaking and teaching; Ortho Biotech Honoraria Speaking and teaching

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.